Number of Participants With Any Adverse Event (AE): Interim Analysis;Number of Participants With Any Adverse Event (AE): Final Analysis;Change From Baseline in the Indicated Clinical Chemistry Parameters at Weeks 48, 96, 120, 132, 168, 180, 204, and 216;Median Values of the Indicated Clinical Chemistry Parameters at Weeks 120, 180, 204, 216, and 432;Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 120, 180, 204, and 216;Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 96, 132, and 168;Median Value of the Total Cholesterol/HDL Ratio at Weeks 120, 180, 204, 216, and 432;Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 120, 180, 204, and 216;Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 96, 132, and 168;Median Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase Values at Weeks 120, 180, 204, 216, and 432;Number of Participants With Any Adverse Event (AE): Interim Analysis;Number of Participants With Any Adverse Event (AE): Final Analysis;Change From Baseline in the Indicated Clinical Chemistry Parameters at Weeks 48, 96, 120, 132, 168, 180, 204, and 216;Median Values of the Indicated Clinical Chemistry Parameters at Weeks 120, 180, 204, 216, and 432;Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 120, 180, 204, and 216;Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 96, 132, and 168;Median Value of the Total Cholesterol/HDL Ratio at Weeks 120, 180, 204, 216, and 432;Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 120, 180, 204, and 216;Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 96, 132, and 168;Median Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase Values at Weeks 120, 180, 204, 216, and 432